G. A. Taylor

2-[11C]Thymidine Positron Emission Tomography as an Indicator of Thymidylate Synthase Inhibition in Patients Treated With AG337

Paula Wells, Eric O. Aboagye, Roger N. Gunn et al. · JNCI Journal of the National Cancer Institute · 2003 · 61 citations · Full text

Thymidylate synthase: A target for anticancer drug design

K.R. Harrap, Ann L. Jackman, David R. Newell et al. · Advances in Enzyme Regulation · 1989 · 51 citations

Medicine, Synthetic Biology, Thymidylate Synthase +4

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer

Simon W. Pridgeon, Rakesh Heer, G. A. Taylor et al. · British Journal of Cancer · 2011 · 49 citations · Full text

Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance

A H Calvert, Terence R. Jones, P J Dady et al. · European Journal of Cancer (1965) · 1980 · 43 citations

Pharmaceutical Chemistry, Biochemistry, Medicine +9

Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion.

Imran Rafi, G. A. Taylor, J A Calvete et al. · PubMed · 1995 · 39 citations

Pharmacotherapy, Clinical Pharmacokinetic, Pharmacodynamic Studies +16